Physician profile
Paige Bruning
NPI 1023562212
$6,026.65
in general payments reported to CMS, 2019-2025
29 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $1,284 · 2023: $2,296 · 2024: $1,997 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,512 · Education: $18.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,511.83 |
| Education | $18.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,420.37 | 2021-2025 | |
| Gilead Sciences, INC. | $793.96 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $650.18 | 2021-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $453.07 | 2021-2024 | Stelara, Simponi Aria, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $419.77 | 2021-2024 | Xifaxan |
| Genzyme Corporation | $371.12 | 2022-2025 | |
| Celgene Corporation | $328.61 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $312.41 | 2022-2024 | Dupixent |
| Pfizer INC. | $197.77 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $137.10 | 2021-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $112.42 | 2021-2024 | Rebyota |
| Daiichi Sankyo INC. | $101.33 | 2022-2024 | Injectafer |
| Ardelyx, INC. | $95.95 | 2022-2023 | Ibsrela |
| Organon LLC | $77.67 | 2023-2024 | Renflexis |
| Nestle Healthcare Nutrition INC. | $64.96 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.73 | 2023-2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.38 | 2023 | Cyltezo |
| Qol Medical, LLC | $56.68 | 2022-2024 | Sucraid |
| Fresenius Kabi USA, LLC | $55.80 | 2023 | Idacio |
| Mylan Institutional INC. | $46.66 | 2023 | |
| Merck Sharp & Dohme LLC | $44.37 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $33.29 | 2023-2024 | Linzess |
| Enterra Medical, INC. | $27.02 | 2024 | |
| Digestive Care, INC. | $21.71 | 2024 | Pertzye |
| Madrigal Pharmaceuticals | $19.13 | 2024 | Resmetirom |
| Csl Behring | $19.06 | 2022 | |
| Novo Nordisk INC | $16.64 | 2023 | Wegovy |
| Aimmune Therapeutics, INC. | $14.35 | 2024 | |
| Redhill Biopharma INC. | $14.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Bruning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.